Royalty Pharma plc
RPRX
NASDAQ·Healthcare·Medical - Pharmaceuticals·Mkt cap $28.4B
$63.96
▲ +0.13%
P/E
33.84
Mkt Cap
$28.4B
52-Wk Range
$34.08–$64.38
52-Week Range
$34.08 - $64.38
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 78.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Diversified portfolio of 35+ marketed therapies reducing concentration risk
- Recurring, predictable royalty revenue streams independent of R&D execution
- Deep industry relationships with academic, biotech, and pharmaceutical partners
- Established deal-sourcing network providing deal flow advantages
- Experienced management team with pharmaceutical and finance expertise
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Strong growth ahead
Expansion of royalty portfolio through strategic acquisitions
Value
Undervalued - trading well below Biotech & Therapeutics peers
Momentum
Strong
+16.6% over 3m
Quality
Excellent
Excellent business quality
Dividend
Modest
1.45% yield
Smart-money signal
Who's buying RPRX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of $1.32 vs $1.27 consensus (+3.9% surprise). Revenue of $773.0M vs $758.9M expected (+1.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+3.9%
Revenue trend · last 8Q
—
-0%
+0%
+8%
+8%
+5%
+11%
+17%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$564.7M
$593.6M
$568.2M
$578.7M
$609.3M
$622.0M
$630.6M
$674.1M
Margins · last 8Q
Gross
60.2%
Operating
19.7%
Profit
2.6%
Wall Street consensus
6 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Goldman Sachs · Aug 6, 2026
vs Industry
How RPRX stacks vs Medical - Pharmaceuticals
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related